Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an estimate of the cost to the public purse of increasing the National Institute for Health and Care Excellence cost-effectiveness threshold by 25%.

The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.

That is why through our Life Sciences Sector Plan, we have committed to working with industry to accelerate growth in spending on innovative medicines, compared to the previous decade. Our 10-Year Health Plan sets out how we will reform the National Institute for Health and Care Excellence.